Supported by Investment Zone funding, the Microbiome and Infectious Disease (MaID) Innovation Hub will drive development and commercialisation of microbiome therapies, novel antimicrobials and diagnostics for infectious disease.
Microbiomes - communities of microorganisms - offer a new frontier in tackling infectious disease, cancer, inflammatory bowel disease and mental health. They are also an important source of novel antimicrobials such as bacteriophage that can act as alternatives to antibiotics and help to tackle global antimicrobial resistance (AMR).
MaID will harness the world-leading expertise of the University of Liverpool’s Microbiome Innovation Centre (MIC), and Liverpool Science Park-based High Value Manufacturing Catapult CPI, alongside manufacturer TriRx Speke, to provide end-to-end support for businesses and organisations seeking to de-risk and to accelerate microbiome and phage therapeutics to market.
Through scientific consultancy, access to cutting-edge technology, a strong partnership network and a rich range of guidance relating to funding, regulatory, IP, manufacturing and more, MaID will position Liverpool as the place where life science innovators thrive.
Contact: mic@liverpool.ac.uk
Back to: Collaborate with us